Agreement represents a working relationship that will involve joint marketing efforts and a mutual contracting of complementary products and services.
Framingham, Massachusetts, and Bogota, Colombia – February 9, 2006 – Averion Inc. (Averion) a leading Contract Research Organization with more than 20 years experience, announced today that it has signed a non-exclusive alliance agreement with SIPLAS Research Organization Inc. (SIPLAS RO). SIPLAS RO is a full-service Contract Research Organization, which provides Phase II-IV services for clinical trials conducted in Latin America.
This agreement represents a working relationship that will involve joint marketing efforts and a mutual contracting of complementary products and services from both companies to biotechnology, pharmaceutical and medical device companies. Among the areas where a partnership would appear to be beneficial to both parties are cases when Averion may wish to conduct multi-national studies including Latin America or when SIPLAS RO may wish to conduct multi-national studies including North America.
"We are very excited about this alliance with SIPLAS RO," said Brian Langin, Averion's Associate Director of Business Development and Strategic Alliances. "We now have the ability to offer our clients the assurance of a Latin American partner who has the same level of quality, integrity and commitment that Averion is recognized for."
"The alliance with Averion brings us a depth of operational experience in clinical research that perfectly integrates with our objective to support global trials that includes sites throughout Latin America," says Juan D. Gutierrez, President of SIPLAS Research Organization Inc.
About Averion:
Averion provides clinical trials support for biotech, pharmaceutical and medical device companies in the design, execution and reporting of clinical trials. Services include Program Planning, Study Design, Clinical Monitoring, Medical Monitoring, Data Management, Database Development, Biometrics, Medical Writing, Data Monitoring Committees, Compliance and Validation, and FDA Representation. Averion's corporate headquarters are located in Framingham, Massachusetts. Visit Averion's website at www. averioninc.com.
About SIPLAS RO:
SIPLAS Research Organization is a specialty, technology-based CRO dedicated to conducting superior Phase II-IV clinical trials in the Andean region countries of Latin America. Our network of qualified investigators in multiple therapeutic areas is located in premier sites in Peru, Ecuador, Colombia, Panama and Venezuela. Our geographic reach is extended to additional countries in Latin America through partnerships with other local CROs in Mexico, Argentina and Brazil. Access to these research sites allow SIPLAS RO to meet the increasing needs of biotech and pharmaceutical companies, with enrollment speed unsurpassed anywhere. SIPLAS RO maintains global standards and implements the best talent, infrastructure and technology available to deliver developed-world services from that region. Visit SIPLAS RO's website at www.siplasro.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.